AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
After a phase 3 push the livmoniplimab plan falters.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
The company discontinues one of its two KRAS G12D degraders.
With a slashed valuation the newly listed biotech heads for phase 3.
An actinium-based backup and Werner helicase inhibitor are notable absences.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
